Emergence of resistance to anti-cancer drugs currently limits the application of relatively specific new drugs. We are interested in resolving the underlying mechanisms and, accordingly, offer novel combinations of drugs.
Area:
Life Sciences
Thursday, September 30, 2021
Adaptive changes enable cancer cells to evade the apoptosis-inducing effects of anti-cancer drugs. We are interested in kinase inhibitors and monoclonal anti-tumor antibodies, which are often highly effective initially, but frequently loose activity due to adaptations and emergence of new mutations. Once the underlying mechanisms of drug resistance are resolved a new drug combination might be offered. The emergence of new mutations is driven by mutators that interfere with the normal function of the DNA replication fork, which is the focus of our studies. Similarly, we are interested in checkpoint inhibitors, such as PD-L1, the underlying oncogenic effects and ways to enhance responses to checkpoint inhibitors.